Hereditary Thrombophilia in the Era of COVID-19

Thrombophilia, also called hypercoagulability or prothrombotic condition, usually reflects a certain imbalance that occurs either in the coagulation cascade or in the anticoagulation/fibrinolytic system. A similar imbalance may be induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare (Basel) 2022-05, Vol.10 (6), p.993
Main Authors: Badulescu, Oana Viola, Sirbu, Paul Dan, Filip, Nina, Bordeianu, Gabriela, Cojocaru, Elena, Budacu, Cristian Constantin, Badescu, Minerva Codruta, Bararu-Bojan, Iris, Veliceasa, Bogdan, Ciocoiu, Manuela
Format: Article
Language:English
Subjects:
Anticoagulants
Blood clot
Coronaviruses
COVID-19
Mortality
Review
Risk factors
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombophilia, also called hypercoagulability or prothrombotic condition, usually reflects a certain imbalance that occurs either in the coagulation cascade or in the anticoagulation/fibrinolytic system. A similar imbalance may be induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Thrombotic complications are associated with multiorgan failure and increased mortality. In this context, activation of coagulation and thrombocytopenia appeared as prognostic markers in COVID-19. Our work provides a structured and updated analysis of inherited thrombophilia and its involvement in COVID-19, emphasizing the importance of diagnosing and initiating thromboprophylaxis. Since the state of hypercoagulation is directly correlated with COVID-19, we consider that studies on the genetic profiles of proteins involved in thrombophilia in patients who have had COVID-19 and thrombotic events are of great importance, both in treating and in preventing deaths due to COVID-19.
ISSN:2227-9032
2227-9032
DOI:10.3390/healthcare10060993